Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Altimmune (ALT) Current Assets (2016 - 2025)

Historic Current Assets for Altimmune (ALT) over the last 17 years, with Q3 2025 value amounting to $216.6 million.

  • Altimmune's Current Assets rose 4861.17% to $216.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $216.6 million, marking a year-over-year increase of 4861.17%. This contributed to the annual value of $137.3 million for FY2024, which is 3452.43% down from last year.
  • According to the latest figures from Q3 2025, Altimmune's Current Assets is $216.6 million, which was up 4861.17% from $188.4 million recorded in Q2 2025.
  • Altimmune's Current Assets' 5-year high stood at $245.2 million during Q1 2021, with a 5-year trough of $137.3 million in Q4 2024.
  • For the 5-year period, Altimmune's Current Assets averaged around $189.7 million, with its median value being $191.1 million (2022).
  • In the last 5 years, Altimmune's Current Assets skyrocketed by 51859.37% in 2021 and then plummeted by 3452.43% in 2024.
  • Altimmune's Current Assets (Quarter) stood at $204.1 million in 2021, then decreased by 5.54% to $192.8 million in 2022, then increased by 8.72% to $209.6 million in 2023, then plummeted by 34.52% to $137.3 million in 2024, then soared by 57.82% to $216.6 million in 2025.
  • Its Current Assets was $216.6 million in Q3 2025, compared to $188.4 million in Q2 2025 and $155.3 million in Q1 2025.